These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 16463553)
81. Comments about the severe fracture concept used in the 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, by Briot et al. Pouilles JM Joint Bone Spine; 2012 Oct; 79(5):527-8; author reply 528-9. PubMed ID: 23041470 [No Abstract] [Full Text] [Related]
83. Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JG. Belaya ZE Rheumatol Int; 2011 Dec; 31(12):1669-71. PubMed ID: 21127879 [No Abstract] [Full Text] [Related]
84. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Watts NB; Bilezikian JP; Camacho PM; Greenspan SL; Harris ST; Hodgson SF; Kleerekoper M; Luckey MM; McClung MR; Pollack RP; Petak SM Endocr Pract; 2010; 16(6):1016-9. PubMed ID: 21216723 [No Abstract] [Full Text] [Related]
85. Not all SERMs are created equal: chapter 2. Goldstein SR Menopause; 2015 Aug; 22(8):802-3. PubMed ID: 26102533 [No Abstract] [Full Text] [Related]
86. KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease. Woo KT; Chan CM Kidney Int; 2011 Sep; 80(5):553-4; author reply 554. PubMed ID: 21841837 [No Abstract] [Full Text] [Related]
87. Ibandronate (Boniva): a new oral bisphosphonate. Obstet Gynecol; 2005 Aug; 106(2):404. PubMed ID: 16055598 [No Abstract] [Full Text] [Related]
88. New drugs: entecavir, ibandronate sodium, and pegaptanib sodium. Hussar DA J Am Pharm Assoc (2003); 2005; 45(3):412-5. PubMed ID: 15991765 [No Abstract] [Full Text] [Related]
89. Injectable drug dampens bone loss. Health News; 2003 Dec; 9(12):11. PubMed ID: 14679970 [No Abstract] [Full Text] [Related]
90. Fractures and ventilator dependence in neonates: Is the use of bisphosphonates an appropriate consideration? White M; Pellicano A; Zacharin MR; Simm PJ J Paediatr Child Health; 2016 Nov; 52(11):1042-1044. PubMed ID: 29048722 [No Abstract] [Full Text] [Related]
91. Secondary Fracture Prevention: Consensus Clinical Recommendations From a Multistakeholder Coalition. Conley RB; Adib G; Adler RA; Åkesson KE; Alexander IM; Amenta KC; Blank RD; Brox WT; Carmody EE; Chapman-Novakofski K; Clarke BL; Cody KM; Cooper C; Crandall CJ; Dirschl DR; Eagen TJ; Elderkin AL; Fujita M; Greenspan SL; Halbout P; Hochberg MC; Javaid M; Jeray KJ; Kearns AE; King T; Koinis TF; Koontz JS; Kužma M; Lindsey C; Lorentzon M; Lyritis GP; Michaud LB; Miciano A; Morin SN; Mujahid N; Napoli N; Olenginski TP; Puzas JE; Rizou S; Rosen CJ; Saag K; Thompson E; Tosi LL; Tracer H; Khosla S; Kiel DP Orthop Nurs; 2020; 39(3):145-161. PubMed ID: 32443087 [No Abstract] [Full Text] [Related]
92. Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical "two-hit" model. Golub LM; Payne JB; Reinhardt RA; Nieman G J Dent Res; 2006 Feb; 85(2):102-5. PubMed ID: 16434727 [No Abstract] [Full Text] [Related]
93. Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate. Armstrong DJ; Wright SA; Coward SM; Finch MB Ann Rheum Dis; 2006 Jul; 65(7):976-7. PubMed ID: 16769790 [No Abstract] [Full Text] [Related]
94. Things We Do for No Reason™: Deferring bisphosphonate initiation to the outpatient setting after fragility hip fracture. Freeman S; Mujahid N J Hosp Med; 2024 May; 19(5):417-420. PubMed ID: 37545423 [No Abstract] [Full Text] [Related]
96. A new option for osteoporosis. Johns Hopkins Med Lett Health After 50; 2005 Jul; 17(5):7. PubMed ID: 16138408 [No Abstract] [Full Text] [Related]
97. Commentary on an article by Jacob S. Vandermeer et al.: "Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head. A combined therapy that stimulates bone formation and decreases femoral head deformity". Baumgarten KM J Bone Joint Surg Am; 2011 May; 93(10):e57. PubMed ID: 21593363 [No Abstract] [Full Text] [Related]
98. [Ibandronate once a month]. Polk B Med Monatsschr Pharm; 2006 Jan; 29(1):36-7. PubMed ID: 16463553 [No Abstract] [Full Text] [Related]
99. [Does ibandronate (Bonviva) have an impact on non-vertebral fractures?]. Kastelan D; Vlak T Reumatizam; 2007; 54(2):87-8. PubMed ID: 18351153 [No Abstract] [Full Text] [Related]
100. Intravenous ibandronate (Boniva). Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):68-9. PubMed ID: 16977282 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]